Brokerages Set Personalis, Inc. (NASDAQ:PSNL) Target Price at $7.67

Shares of Personalis, Inc. (NASDAQ:PSNL - Get Free Report) have earned a consensus recommendation of "Buy" from the six research firms that are covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $7.67.

PSNL has been the subject of a number of research analyst reports. HC Wainwright increased their price objective on shares of Personalis from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, May 7th. Needham & Company LLC reaffirmed a "buy" rating and set a $7.00 price objective on shares of Personalis in a research report on Thursday, April 10th. Guggenheim initiated coverage on shares of Personalis in a research report on Thursday, May 15th. They set a "buy" rating and a $6.00 price objective for the company. Finally, Craig Hallum initiated coverage on shares of Personalis in a research note on Monday, March 17th. They issued a "buy" rating and a $8.00 price target for the company.

Personalis Stock Down 10.3%

Shares of Personalis stock traded down $0.77 during mid-day trading on Friday, hitting $6.68. The stock had a trading volume of 1,944,382 shares, compared to its average volume of 1,146,530. The firm has a market cap of $589.98 million, a P/E ratio of -5.18 and a beta of 1.95. The firm has a 50-day moving average of $5.42 and a two-hundred day moving average of $4.85. Personalis has a 12-month low of $1.41 and a 12-month high of $7.79.

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05. The firm had revenue of $20.61 million during the quarter, compared to analysts' expectations of $17.41 million. Personalis had a negative net margin of 98.10% and a negative return on equity of 48.78%. Sell-side analysts expect that Personalis will post -1.4 earnings per share for the current year.

Hedge Funds Weigh In On Personalis

Several institutional investors have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its stake in shares of Personalis by 55.7% during the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company's stock worth $998,000 after purchasing an additional 101,706 shares in the last quarter. Focus Partners Wealth acquired a new position in shares of Personalis during the first quarter worth $47,000. Dynamic Technology Lab Private Ltd grew its stake in shares of Personalis by 75.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company's stock worth $269,000 after purchasing an additional 33,044 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Personalis by 3.2% during the first quarter. Royal Bank of Canada now owns 78,341 shares of the company's stock worth $275,000 after purchasing an additional 2,395 shares in the last quarter. Finally, Trexquant Investment LP grew its stake in shares of Personalis by 455.0% during the first quarter. Trexquant Investment LP now owns 122,959 shares of the company's stock worth $432,000 after purchasing an additional 100,804 shares in the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.